News: MDR Medadvisor Says Completed Strategic Review Of Its Operations

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    June 22 (Reuters) - Medadvisor Ltd (MDR) :

    • COMPLETED A STRATEGIC REVIEW OF ITS OPERATIONS
    • FY23 REVENUE EXPECTED TO BE IN RANGE OF A$95 MILLION TO A$97 MILLION
    • PLANS TO REDUCE ITS AUSTRALIAN HEADCOUNT BY APPROXIMATELY 20% BY END OF JUNE 2023
    • FY 23 EBITDA LOSS EXPECTED TO BE IN RANGE A$3.5 MILLION TO A$3.0 MILLION
    • REDUCTION IN HEADCOUNT UNDERPINS ANNUAL COST SAVINGS OF CIRCA A$2 MILLION FOR FY24
    • HAS POSITIONED ITSELF FOR PROFITABILITY IN FY24
    • COMPANY'S CURRENT US PIPELINE IS MATERIALLY ABOVE PREVIOUS CORRESPONDING PERIOD
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
6.0¢
Change
0.002(3.45%)
Mkt cap ! $37.51M
Open High Low Value Volume
6.0¢ 6.0¢ 5.7¢ $18.06K 311.5K

Buyers (Bids)

No. Vol. Price($)
1 26172 5.8¢
 

Sellers (Offers)

Price($) Vol. No.
6.0¢ 27587 2
View Market Depth
Last trade - 16.10pm 21/08/2025 (20 minute delay) ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.